Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Royalty Pharma plc is one of them.

Royalty Pharma plc (NASDAQ:RPRX), a leader in biopharma royalties, made major strategic moves in September 2025. The company completed a $2 billion senior notes offering maturing in 2031, 2035, and 2055, enhancing its ability to acquire long-duration royalty assets, fund deals, and strengthen its capital structure.

The firm continues to benefit from growing adoption of royalties, with 87% of biopharma executives considering them for capital needs. Since its 2020 IPO, the corporation has tripled headcount, invested in data analytics, and streamlined operations through manager internalization. Q2 2025 portfolio receipts rose 20% year-over-year, and the company targets $4.7 billion in receipts by 2030, with mid-teens shareholder returns and dividend growth. These trends position Royalty Pharma plc (NASDAQ:RPRX) among the best pharmaceutical stocks for long-term growth.

Innovation drives its growth, particularly in oncology. Royalty Pharma plc (NASDAQ:RPRX) announced a $2 billion funding deal with Revolution Medicines, including up to $1.25 billion in synthetic royalties on daraxonrasib, a late-stage compound targeting RAS-addicted cancers.

Royalty Pharma plc (NASDAQ:RPRX) will present at Bernstein’s 2nd Annual Healthcare Forum on September 23, 2025. Analysts remain bullish, with TD Cowen reaffirming a buy rating and a $42 price target, reflecting strong performance and promising future growth.

While we acknowledge the potential of RPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.